Track topics on Twitter Track topics that are important to you
Toulouse, France & Ann Arbor, Michigan, June 21, 2010—Cerenis Therapeutics SA (Cerenis), a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.
Niacin (NA) has proven cardiovascular benefit, including reduction in morbidity and mortality, however, its usage has been limited by facial flushing. This side effect often prevents patients from titrating to adequate dose levels and frequently results in discontinuation of dosing altogether. Current niacin prescribing recommendations advise taking aspirin 30 minutes prior to niacin in order to inhibit COX1-dependent prostaglandin production in the skin, which is responsible for niacin-induced flushing. However, because aspirin is rapidly metabolized and removed from the circulation, its effectiveness is limited. Better anti-flushing effects may be achieved by controlling and coordinating aspirin and niacin exposure such that aspirin is present at sufficient levels in the skin prior to, and during niacin exposure (Kuhrts et al. 1999. US patent 5,981,555).
Two Phase 1 proof-of-concept studies were conducted to evaluate simulated sustained-release aspirin regimens to decrease niacin-induced flushing. In the first study, 4 days of pre-dosing with 240 mg of aspirin, followed by a simulated sustained-release aspirin treatment regimen (20 mg/hr for 12 hrs), given in conjunction with 500 mg of immediate-release niacin at hour 6, was assessed in 30 subjects for its ability to inhibit niacin-induced flushing. The aspirin regimen resulted in a highly significant 53% reduction in the Maximal Severity of Flushing (MSF) (p=0.002) compared with Placebo. In the second study, flushing induced by a single 2g dose of extended release-niacin (Niaspan®) was evaluated with two different sustained-release aspirin dosing regimens in 54 subjects. Regimen A consisted of 3 days of pre-dosing with 240 mg of aspirin, followed by aspirin 30 mg/kg for 8 hrs with extended-release niacin administered at hour 4. Regimen B consisted of no aspirin pre-dosing and aspirin 10 mg/hr for 6 hrs with extended-release niacin administered at hour 6. Regimen A significantly reduced the MSF by 37% compared with Placebo (p=0.0003) whereas regimen B had no significant effect (p=0.094). It was concluded that the timing and duration of aspirin exposure relative to niacin is important in inhibiting niacin-induced flushing.
These data support the development of a fixed-dose combination product of sustained-release aspirin and delayed and extended-release niacin. Such a product would be expected to increase patient compliance thereby allowing niacin to attain its full potential for cardiovascular protection.
Notes to editors:
Details for the poster presentation are as follows:
Monday, June 21, 2010, 5:30 PM–8:30 PM
Tuesday, June 22, 2010, 1:00 PM–3:00 PM
Abstract Title: Optimized Aspirin Dosing Regimen for Reduction of Niacin-induced Flushing (Presentation # A-226-0001-00099)
Authors: Cynthia Sundell, Constance Keyserling, Heather Klepp, Ronald Goldwater* and Rob Scott (Cerenis Therapeutics, SA, Labege France; *PAREXEL Early Phase Unit, Baltimore MD, USA)
The goal of the CER-627 program is to develop a fixed dose combination of niacin and aspirin to treat dyslipidemia with low HDL, where the aspirin dosing is delivered by sustained release several hours in advance of niacin dosing. This dosing combination has an unexpectedly large ability to reduce flushing, and is supported by a portfolio of issued and pending patents. CER-627 is under phase 2 clinical development, with a focus on formulation optimization.
Cerenis Therapeutics is a multinational biopharmaceutical company dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and HDL elevators for patients with low HDL. Cerenis is well positioned to become the leader in the HDL therapeutic market with a broad portfolio of programs in development.
For further information, please contact:
Jean-Louis Dasseux, President and CEO
Tel: +33 (0) 5 62 24 97 06
Bill Brinkerhoff, Chief Operating Officer
Tel: +1 734 769 1110 x217
College Hill Life Sciences
Melanie Toyne Sewell
+44 20 7457 2020
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...